A randomised controlled pilot study of standardised counselling and cost-free pharmacotherapy for smoking cessation among stroke and TIA patients

Sophia Papadakis, Debbie Aitken, Sophia Gocan, Dana Riley, Mary Ann Laplante, Abha Bhatnagar-Bost, Donna Cousineau, Danielle Simpson, Rojiemiahd Edjoc, Andrew L Pipe, Mukul Sharma, Robert D Reid, Sophia Papadakis, Debbie Aitken, Sophia Gocan, Dana Riley, Mary Ann Laplante, Abha Bhatnagar-Bost, Donna Cousineau, Danielle Simpson, Rojiemiahd Edjoc, Andrew L Pipe, Mukul Sharma, Robert D Reid

Abstract

Background Tobacco use is a major risk factor for recurrent stroke. The provision of cost-free quit smoking medications has been shown to be efficacious in increasing smoking abstinence in the general population. Objective The objective of this pilot study was to assess the feasibility and obtain preliminary data on the effectiveness of providing cost-free quit smoking pharmacotherapy and counselling to smokers identified in a stroke prevention clinic. Trial design Cluster randomised controlled trial. Methods All patients seen at the Ottawa Hospital Stroke Prevention Clinic who smoked more five or more cigarettes per day, were ready to quit smoking in the next 30 days, and were willing to use pharmacotherapy were invited to participate in the study. All participants were advised to quit smoking and treated using a standardised protocol including counselling and pharmacotherapy. Participants were randomly assigned to either a prescription only usual care group or an experimental group who received a 4-week supply of cost-free quit smoking medications and a prescription for medication renewal. All patients received follow-up counselling. The primary outcome was biochemically validated quit rates at 26 weeks. The research coordinator conducting outcome assessment was blind to group allocation. Results Of 219 smokers screened, 73 were eligible, 28 consented and were randomised, and 25 completed the 26-week follow-up assessment. All 28 patients randomised were included in the analysis. The biochemically validated 7-day point prevalence abstinence rate in the experimental group compared to the usual care group was 26.6% vs 15.4% (adjusted OR 2.00, 95% CI 0.33 to 13.26; p=0.20). Conclusions It would be feasible to definitively evaluate this intervention in a large multi-site trial. Trial registration number http://ClinicalTrials.gov # UOHI2010-1.

Conflict of interest statement

Competing interests: The institutions and study authors at no time received payment or services from a third party for any aspect of the work submitted. The University of Ottawa Heart Institute has received research and education grant support from Pfizer Canada, Johnson and Johnson, and GlaxoSmithKline. AP has served as a consultant and has received speaker honoraria from Pfizer, Johnson and Johnson, and GlaxoSmithKline; RR has received speaker honoraria from Pfizer; DA has received speaker honoraria from Pfizer; and DR has served as a consultant to Pfizer.

Figures

Figure 1
Figure 1
CONSORT (Consolidated Standards of Reporting Trials) diagram.

References

    1. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989;298:789–94
    1. Wolf PA, D'Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA 1988;259:1025–9
    1. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. Ann Intern Med 1993;119:992–1000
    1. Ovbiagele B, Saver JL, Fredieu A, et al. In-hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow-up. Stroke 2004;35:2879–83
    1. Wannamethee SG, Shaper AG, Whincup PH, et al. Smoking cessation and the risk of stroke in middle-aged men. JAMA 1995;274:155–60
    1. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation 1997;96:1089–96
    1. Naidoo B, Stevens W, McPherson K. Modelling the short term consequences of smoking cessation in England on the hospitalisation rates for acute myocardial infarction and stroke. Tob Control 2000;9:397–400
    1. Mouradian MS, Majumdar SR, Senthilselvan A, et al. How well are hypertension, hyperlipidemia, diabetes, and smoking managed after a stroke or transient ischemic attack? Stroke 2002;33:1656–9
    1. Bak S, Sindrup SH, Alslev T, et al. Cessation of smoking after first-ever stroke: a follow-up study. Stroke 2002;33:2263–9
    1. Johnson P, Rosewell M, James MA. How good is the management of vascular risk after stroke, transient ischaemic attack or carotid endarterectomy? Cerebrovasc Dis 2007;23:156–61
    1. Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Am J Prev Med 2008;35:158–76
    1. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;(1):CD000146.
    1. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007;(1):CD000031.
    1. Furie KL, Kasner SE, Adams RJ, et al. ; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011;42:227–76
    1. Lindsay MP, Gubitz G, Bayley M, et al. ; On behalf of the Canadian Stroke Strategy Best Practices and Standards Writing Group. Canadian Best Practice Recommendations for Stroke Care (Update 2010). Ottawa, Ontario Canada: Canadian Stroke Network, 2010
    1. Ismailov RM, Leatherdale ST. Smoking cessation aids and strategies among former smokers in Canada. Addict Behav 2010;35:282–5
    1. Balmford J, Borland R, Hammond D, et al. Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey. Nicotine Tob Res 2011;13:94–102
    1. Smeeth L, Fowler G. Nicotine replacement therapy for a healthier nation. Nicotine replacement is cost effective and should be prescribable on the NHS. BMJ 1998;317:1266–7
    1. Vogt F, Hall S, Marteau TM. Understanding why smokers do not want to use nicotine dependence medications to stop smoking: qualitative and quantitative studies. Nicotine Tob Res 2008;10:1405–13
    1. Cummings KM, Fix B, Celestino P, et al. Reach, efficacy, and cost-effectiveness of free nicotine medication giveaway programs. J Public Health Manag Pract 2006;12:37–43
    1. Cummings KM, Hyland A, Fix B, et al. Free nicotine patch giveaway program 12-month follow-up of participants. Am J Prev Med 2006;31:181–4
    1. Kaper J, Wagena EJ, Willemsen MC, et al. Reimbursement for smoking cessation treatment may double the abstinence rate: results of a randomized trial. Addiction 2005;100:1012–20
    1. Twardella D, Brenner H. Effects of practitioner education, practitioner payment and reimbursement of patients' drug costs on smoking cessation in primary care: a cluster randomised trial. Tob Control 2007;16:15–21
    1. Cox AM, McKevitt C, Rudd AG, et al. Socioeconomic status and stroke. Lancet Neurol 2006;5:181–8
    1. Arrich J, Mu¨llner M, Lalouschek W, et al. Influence of socioeconomic status and gender on stroke treatment and diagnostics. Stroke 2008;39:2066–72
    1. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why, and how. BMC Med Res Methodol 2010;10:1.
    1. Reid RD, Mullen KA, Slovinec D'Angelo ME, et al. Smoking cessation for hospitalized smokers: an evaluation of the “Ottawa Model”. Nicotine Tob Res 2010;12:11–18
    1. Reid RD, Pipe AL, Quinlan B. Promoting smoking cessation during hospitalization for coronary artery disease. Can J Cardiol 2006;22:775–80
    1. Crawford JR, Henry JD, Crombie C, et al. Normative data for the HADS from a large non-clinical sample. Br J Clin Psychol 2001;40:429–34
    1. Reda AA, Kaper J, Fikrelter H, et al. Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database Syst Rev 2009;(2):CD004305.
    1. Reid JL, Hammond D, Driezen P. Socio-economic status and smoking in Canada, 1999–2006: has there been any progress on disparities in tobacco use? Can J Public Health 2010;101:73–8
    1. Costa ML, Cohen JE, Chaiton MO, et al. “Hardcore” definitions and their application to a population-based sample of smokers. Nicotine Tob Res 2010;12:860–4
    1. Sauerbeck LR, Khoury JC, Woo D, et al. Smoking cessation after stroke: education and its effect on behavior. J Neurosci Nurs 2005;37:316–19, 325.
    1. Ellis G, Rodger J, McAlpine C, et al. The impact of stroke nurse specialist input on risk factor modification: a randomised controlled trial. Age Ageing 2005;34:389–92

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner